HARPNET HARPNET – Harnessing Resolution Pharmacology for Next-Generation Therapeutics
- Coordinator
- Queen Mary University of London, United Kingdom
- Runs
- 1 October 2026 to 30 September 2030
- Status
- Running
- EU funding
- €4.8m
- Total cost
- —
- Partners
- 25 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101311747
What the project is doing
In the project's own words, from its summary on CORDIS.
Chronic inflammatory diseases and their comorbidities pose a major global health burden, with conditions such as rheumatoid arthritis (RA) and associated cardiovascular disease (CVD) affecting hundreds of millions worldwide. Current anti-inflammatory therapies alleviate symptoms but rarely restore tissue homeostasis, leaving patients at risk of persistent inflammation and long-term damage. Addressing this challenge requires researchers trained not only in classical immunology and pharmacology but also in the emerging field of Resolution Pharmacology, which aims to activate endogenous pathways that terminate inflammation and promote tissue repair.
Yet the interdisciplinary expertise required, spanning resolution biology, GPCR signalling, advanced multi-omics, systems analysis, and translational development, is not available within existing programmes, creating a critical skills gap that limits progress. HARPNET addresses this unmet need through an innovation-driven training programme uniting 14 beneficiaries and 11 associated partners. Fifteen Doctoral Candidates (DCs) will be embedded in cross-disciplinary teams that co-develop cutting-edge methodologies, including integrated multi-omic pipelines, systems-level disease models, and next-generation approaches to target pro-resolving pathways.
This will equip DCs with the scientific, technical, and translational competencies required to drive mechanism-based therapeutic innovation. Using RA and RA-associated CVD as clinically relevant models, HARPNET will deliver hands-on, systems-level, cross-sectoral training across academic, clinical, and industrial settings. Through this comprehensive and co-creative programme, DCs will bridge discovery research with therapeutic development, generating transferable tools and knowledge that extend beyond the network.
HARPNET will strengthen Europe’s long-term capacity to lead in Resolution Pharmacology and to train the next generation of innovators in inflammation research.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Queen Mary University of London | London | United Kingdom | Coordinator |
| Basf Se | Ludwigshafen Am Rhein | Germany | Associatedpartner |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Friedrich-Schiller-Universität Jena | Jena | Germany | Participant |
| Universitaet Zu Luebeck | Lubeck | Germany | Associatedpartner |
| Universitat Rostock | Rostock | Germany | Participant |
| Universitatsklinikum Schleswig-Holstein | Lübeck | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Associatedpartner |
| Synact Pharma Aps | Holte | Denmark | Associatedpartner |
| Universidad Autonoma De Madrid | Madrid | Spain | Participant |
| Ambiotis | Toulouse | France | Participant |
| Med'inn'pharma | Placey | France | Associatedpartner |
| Universite De Toulouse | Toulouse | France | Associatedpartner |
| University College Dublin, National University of Ireland, Dublin | Dublin | Ireland | Participant |
| Flowview Diagnostics BV | Heerenveen | Netherlands | Associatedpartner |
| Qvq Holding B.v. | Utrecht | Netherlands | Associatedpartner |
| Stichting Vu | Amsterdam | Netherlands | Participant |
| Universiteit Maastricht | Maastricht | Netherlands | Participant |
| Arctic Nutrition AS | Orsta | Norway | Associatedpartner |
| Universitetet I Oslo | Oslo | Norway | Participant |
| AB Sciex UK Limited | Warrington | United Kingdom | Associatedpartner |
| Arthritis Research UK | Chesterfield | United Kingdom | Associatedpartner |
| Galvani Bioelectronics Limited | Brentford | United Kingdom | Associatedpartner |
| Glaxosmithkline Research & Development Limited | London | United Kingdom | Associatedpartner |
| University of Glasgow | Glasgow | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI